Promising new combo offers hope for stomach cancer patients who fail immunotherapy
Disease control
Recruiting now
This study is for people with advanced stomach cancer that has spread and no longer responds to first-line immunotherapy. It tests a new combination of three drugs: a targeted therapy (fruquintinib), a chemotherapy (nab-paclitaxel), and a novel immunotherapy (iparomlimab and tuvo…
Phase: PHASE2 • Sponsor: Dai, Guanghai • Aim: Disease control
Last updated May 26, 2026 12:10 UTC